Product Details


  • image description
  • image description

Complete Your Bone Health Regimen

  • Increases bone density
  • Reduces bone loss and fracture risk
  • A combination of the two most powerful bone building nutrients, exclusively available from AOR


Use this product for:

AOR’s Advanced Bone Protection Strontium is an innovative product combining two novel and effective nutrients that work together to improve bone health.  These two nutrients are Milk Basic Protein (or MBP™), a nutrient extracted from the whey fraction of milk, and the mineral strontium. 

MBP has been shown to increase the activity of bone-building cells (called osteoblasts) while reducing the activity of the cells that break down bone (called osteoclasts), resulting in a more balanced and effective approach to preventing the bone loss that leads to osteopenia and osteoporosis. It also helps the bones to retain and use calcium more effectively, and to produce more collagen, which is an important part of the bone matrix.

Strontium, unlike osteoporosis drugs that only reduce bone loss, actually increases osteoblast production while decreasing osteoclast production, resulting in increased bone development and decreased bone loss. Since strontium is similar in molecular structure to calcium, strontium is thought to activate the calcium receptors in the bone, allowing the calcium to be used effectively in bone tissue. Long term strontium supplementation has been shown to continually improve bone density and reduce the risk of osteoporotic fractures. 

Advanced Bone Protection Strontium is a perfect adjunct to a calcium-based bone health regimen, and provides hope for those with osteoporosis, osteopenia or who are concerned with their general bone health.


Related products you may be interested in


Advanced Bone Protection Strontium contains MBP™ (Milk Basic Protein), an active protein complex from the whey fraction of milk, and strontium, a trace mineral. Advanced Bone Protection Strontium helps bone health and structure by reducing bone loss (resorption) and supporting bone mineral density.

Product Variations

NPN Product Code Size
80039417 AOR04181 60 V-CAPS

Supplement Facts

Amount Per Serving Amount: 1  V-Cap
341 mg Strontium (from citrate)
20 mg MBP* (a specific basic protein fraction derived from milk)
*MBP is owned by Snow Brand Milk Products Co., Ltd.
Non-medicinal ingredients: Capsule: hypromellose.

AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, corn, nuts, peanuts, sesame seeds, sulphites, mustard, soy, eggs, fish or shellfish.


Suggested Use:

(Adult 50 years and older): Take 2 capsules daily on an empty stomach, at least two hours before or after consuming food, calcium or milk since these can significantly reduce strontium absorption if taken together. Ensure an adequate daily intake of calcium and vitamin D.

Cautions :

This supplement may cause transient increases in levels of creatine kinase that are unassociated with any disorder. Discontinue use and consult a health care practitioner in case of rash or hypersensitivity, as this may be a sign of a serious allergic reaction (DRESS or Stevens-Johnson syndrome). Consult a health care practitioner for use beyond 6 months. Pregnant and breastfeeding women, those who have or are at high risk for blood clots (e.g. if you are temporarily or permanently immobilized, over the age of 80, taking birth control pills, etc.), heart diseases and/or circulatory problems (e.g. Venous Thromboembolism (VTE), heart attack, peripheral arterial disease, stroke, high blood pressure, hyperlipidemia, diabetes, etc.), or have kidney disease must not use this product.  This product is not recommended for people with milk allergies.

Pregnancy/Breastfeeding :


  • Pharmaceutical synthesis
  • Bovine Milk

Main Applications:

  • Bone health
  • Women's health

The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.

Advanced Bone Protection Strontium contains MBP, an active protein complex from the whey fraction of milk, and strontium, a trace mineral which concentrates in the skeletal system. Research suggests that MBP can positively impact bone health by reducing bone loss (resorption) and increasing bone mineral density. Strontium supports the function of osteoblasts (bone building cells) while reducing the differentiation and activity of osteoclasts (bone breakdown cells).

Bone health is one of the greatest concerns in our society. 1 in 3 women over the age of 50 will suffer osteoporotic fractures, as will 1 in 5 men. With such statistics, advances in bone health are a main focus of current research. Some treatments for osteoporosis are inconvenient and associated with side effects. Other solutions may work by similar mechanisms, and some are incompatible with each other.

In Partnership

The mechanisms of Advanced Bone Protection and Strontium are distinct, yet synergistic. Strontium increases bone formation, while MBP reduces the rate at which bone is destroyed. Their actions reduce bone breakdown without reducing the activity of bone building cells. The combination of these two nutrients is therefore a perfect match for effective bone support.

Advanced Bone Protection

Advanced Bone Protection contains Milk Basic Protein (MBP), a nutrient extracted from the whey fraction of milk. The terms ‘milk’ and ‘protein’ refer to the source and type of nutrient respectively, while the term ‘basic’ refers to its alkaline nature.

MBP greatly improves the absorption and retention of calcium within the bones, and it does so in a unique way. Part of MBP’s structure consists of a protein strain known as cystatin C, which inhibits an enzyme called cystein protease. Cystein protease releases calcium from bone and digests collagen in the bone matrix. MBP’s cystatin C blocks this enzyme, as well as other factors that contribute to calcium release from bone.

MBP also enhances the proliferation and activity of bone-building cells called osteoblasts, while at the same time preventing the proliferation and activity of bone-breaking cells (osteoclasts). MBP is capable of suppressing the activity of even the most isolated osteoclast. MBP’s ability to manipulate osteoblasts into producing more collagen is more pronounced than that of other nutrients for bone health. MBP also increases serum concentrations of osteocalcin, which is the major non-collagenous protein in bone.

“Mainichi Hone Kea MBP” is a foods for specified health uses (FOSHU) product. It has been approved to write the next claim, “This product is suitable for those who care about bone health, because it contains MBP that has an effect to increase bone density”, on this product. MBP is a complex of protein with a basic isoelectric point in milk protein. It has been shown that MBP promotes bone formation, suppresses bone resorption, increases bone mineral density, and increases bone strength in in vitro and in vivo studies.


Many are concerned with the loss of bone mass that can occur with increasing age. Calcium and mineral supplements are most commonly taken in an effort to prevent bone loss and increase bone density.

In 2002, AOR was the first company in the world to produce supplemental strontium citrate. Now, two of the most effective bone-growth stimulating nutrients, namely strontium and MBP, can be found in one convenient supplement. Combine this product with a high-quality microcrystalline hydroxyapatite calcium supplement for the best bone support regime on the market.


The effects of MBP in healthy adult women from twenties to fifties were examined in one study. A beverage containing MBP or a placebo beverage without MBP was given to volunteers for six months. The percentage increase of radial bone density was significantly higher in the MBP group than in the placebo group. This result has confirmed that MBP contributes to increased bone density in humans. To sum up, we believe that MAINICHI HONE KEA MBP, which contains MBP that has an effect to increase bone density, contributes to bone health.

Other studies with MBP:

  • In a study among healthy menopausal women, the MBP group reported a bone mineral density (BMD) increase of 1.21% while the placebo group recorded a 0.66% BMD decrease.
  • In another study among healthy adult women, the MBP group gained approximately 70% more bone mineral density than the control group.
  • MBP reduced the number of pits on the bone surface caused by bone resorption by approximately 85% in an in-vitro study.
  • In yet another study among healthy adult females, the MBP group displayed a 3% increase in the BMD of the radius (a forearm bone near the wrist) compared to a 1.3% BMD decrease in the placebo group.
  • MBP was given to a group of normal healthy adult men, after 16 days their serum osteocalcin concentration had increased significantly, urinary markers of bone resorption had decreased significantly, suggesting that MBP promoted bone formation and suppressed bone resorption while maintaining the balance of bone remodeling.


Strontium is a mineral that is thought by many to be essential for the normal development, structure, function and health of the skeletal system. Unlike the existing drugs for osteoporosis treatment, as well as calcium and vitamin D, strontium does not work only by reducing bone resorption, but it actually increases the formation of new bone tissue. Furthermore, animal studies have shown that it boosts bone strength without a negative impact on bone quality, even at extremely high doses.

Strontium works by causing bone building osteoblasts to multiply more quickly, and cellular studies have shown that it causes bone tissue cultures to synthesize more bone matrix and new bone collagen.

One of the main ways strontium exerts its bone building effects is by activating the calcium-sensing receptor (CaR). CaRs are found throughout the body, including in the bones, the kidneys, the gastrointestinal system and several glands of the endocrine system, which are constituents of the body that are central to the regulation of calcium levels. These receptors are activated when calcium attaches to them. CaRs are found on the cells of the parathyroid gland, where parathyroid hormone (PTH) is secreted in response to low calcium levels and causes calcium to be released from bones. Strontium binds to CaRs to prevent the release of PTH.

CaR receptors are responsible for releasing calcitonin from the thyroid, a hormone which blocks the activity of osteoclasts and prevents urinary loss of calcium. CaRs are also found on osteoblasts, and when strontium attaches, they stimulate the proliferation of these bone building cells, making them more active and causing them to deposit more calcium, effectively building bone.

The benefits of strontium’s effects have been impressively demonstrated by clinical trials, which have shown that strontium reduces fracture rates at all sites, including hip and vertebral areas which are the most common fracture areas associated with osteoporosis. Strontium can also reduce the rate of height loss and free patients of back pain.

Aoe S, et al. A controlled trial of the effect of milk basic protein (MBP) supplementation on bone metabolism in healthy menopausal women. Osteoprosis International. 2005 Dec;16(12):2123-8. Epub 2005 Aug 31.

Aoe S, et al. Controlled Trial of the Effects of Milk Basic Protein (MBP) Supplementation on Bone Metabolism in Healthy Adult Women. Biosci. Biotechnol. Biochem. Vol.65 pp.913-918. 2001.

ATSDR. Toxicological profile for strontium. Atlanta,GA: Agency for toxic substances and disease registry US Dept of Health and Human Services. Public Health Services.2001

Comar,CL , Wasserman, RH and Nold, NM. Strontium-Calcium discrimination factors in the rat. Proc. Sco. Exp. Biol. Med.1950;92:859-863

Dahl, SG et-al. Incorporation and distribution of strontium in bone. Bone.2001;28:446-453

Della Rossa et-al. Absorption and retention of ingested strontium and calcium in beagles as a function of age. Nature.1965;205:197-198

Leeuwenkamp,OR et-al. Human pharmacokinetics of orally administered strontium. Calcif. Tissue Int. 1990;47:136-140

Marie,PJ et-al. Mechanisms of action and therapeutic potential of strontium in bone. Calcif. Tissue Int.2001;69:121-129.

Marie,PJ et-al. Effect of low doses of stable strontium on bone metabolism in rats. Mineral Electrolyte Metab. 1985;11:5-13

Matsumoto, A. Effect of strontium chloride on bone resorption induced by prostaglandin E2 in cultured bone. Arch. Toxicol. 1988;62:240-241

Matsuoka Y, et al. Cystatin C in Milk Basic Protein (MBP) and Its Inhibitory Effect on Bone Resorption in Vitro. Biosci. Biotechnol. Biochem. 2002. Vol.66 pp.2531-2536.

McCaslin FE and Janes, HM. The effect of strontium lactate in the treatment of osteoporosis. Proc. Mayo Clinic. 1959;34:329-334

Shorr, E and Carter, AC. The value of strontium as an adjuvant to calcium in the mineralization of the skeleton in osteoporosis in man. Conference on Metabolic Interactions. Eds. EC Reifenstein Jr.,NY.NY.Pub J Macy Foundation 1950 pp144-154.

Sips, AJAM et-al. Intestinal absorption of strontium chloride in healthy volunteers: pharmacokinetics and reproducibility.Br. J Clin Pharmacol. 1996;41:543-549

Sips, AJAM.Absoption kinetics of strontium and calcium in human and experimental animal. Ph.D Thesis. University of Amsterdam. 1994

Skoryna, SC. Effects of oral supplementation with stable strontium. Can Med J. 1981;125:703-712

Skoryna, SC.Metabolic aspects of the pharmacologic uses of trace elements in human subjects with specific references to stable strontium. Trace Subst. Enviorn Health.1984;18:3-23

Skoryna,SC and Fuskova, M. In: Skoryna, SC ed. Handbook of stable strontium.NY;Plenum:1985.p593-617

Storey,E. Strontium “rickets” bone calcium and strontium changes. Austral.Ann. Med. 1961;10:213-222

Takada Y, et al. Milk Basic Protein Increases Bone Mineral Density and Improves Bone Metabolism In Humans. Nutritional Aspects of Osteoporosis 2nd Ed. (2004); pp. 413-429.

Toba S, et al. Milk Basic Protein Promotes Bone Formation and Suppresses Bone Resorption in Healthy Adult Men. Biosci. Biotechnol. Biochem. Vol.65 pp.1353-1357. 2001


Interactive effects of milk basic protein supplements and habitual physical activity on bone health in older women: A 1-year randomized controlled trial.

International Dairy Journal, 2010; 20(10), pp. 724–730

Aoyagia Y, Parka H, Parka S, Yoshiuchib K, Kikuchib H, Kawakamic H, Moritac Y, Onoc A, Shephardd R.J.

A 1-year randomized controlled trial examined effects of milk basic protein (MBP) supplementation (40 mg day−1) and daily physical activity (step count and duration of exercise > 3 metabolic equivalents [METs]) on bone metabolism, forearm bone mineral density (BMD) and a calcaneal osteosonic index (OSI) in 79 females aged 65–86 years. MBP did not affect osteocalcin or bone-specific alkaline phosphatase, but at 12 months, excretion of deoxypyridinoline and cross-linked N-teleopeptides of type I collagen (NTx) were significantly less than in controls. Experimental subjects also maintained BMD and had a 1.5% increase of OSI at 12 months. After adjustments for age and baseline bone parameters, osteocalcin, deoxypyridinoline, NTx and/or OSI at 12 months were significantly related to step count and/or duration of activity > 3 METs. MBP reduced markers of bone loss, particularly in the lower extremities. Reduced resorption of bone was also associated with moderate-intensity/duration exercise, MBP therapy interacting significantly with habitual physical activity.


Milk basic protein increases bone mineral density and improves bone metabolism in healthy young women.

Osteoporos Int. 2007 Mar;18(3):385-90.

Uenishi K, Ishida H, Toba Y, Aoe S, Itabashi A, Takada Y.

Effect of milk basic protein on bone metabolism in healthy young women.

INTRODUCTION: Milk has more beneficial effects on bone health than other food sources. Recent in vitro and in vivo studies have shown that milk whey protein, especially its basic protein fraction (milk basic protein, MBP), contains several components capable of promoting bone formation and inhibiting bone resorption. The object of this study was to examine the effect of MBP on the bone mineral density and bone metabolism of healthy young women.

METHODS: Thirty-five healthy young women were randomly assigned to treatment with either placebo or MBP (40 mg per day) for 6 months. The bone mineral density (BMD) of the lumbar vertebrae L2-L4 of each subject was measured by dual-energy X-ray absorptiometry (DXA) at 0 and 6 months of treatment. Serum and urine indexes of bone metabolism were measured at 0, 3 and 6 months. All subjects completed the study in accordance with the protocol.

RESULTS: The mean rate of gain of lumbar BMD in the MBP group (1.57%) was significantly higher than in the placebo group (0.13%, P=0.042). When compared with the placebo group, urinary cross-linked N-telopeptides of type-I collagen (NTx) were significantly decreased, and serum osteocalcin was significantly increased in the MBP group at 6 months.

CONCLUSION: These results suggested that MBP supplementation was effective in increasing BMD in young women and that this increase in BMD may be primarily mediated through the promotion of bone formation and inhibition of bone resorption by MBP supplementation.


Milk basic protein increases alveolar bone formation in rat experimental periodontitis.

J Periodontal Res. 2007 Feb;42(1):85-9.

Seto H, Toba Y, Takada Y, Kawakami H, Ohba H, Hama H, Horibe M, Nagata T.

BACKGROUND AND OBJECTIVE: It is conceivable that the active components extracted from milk whey protein (i.e. milk basic protein, MBP) stimulate bone formation and suppress bone resorption. Periodontitis is characterized by excessive alveolar bone resorption. We examined whether milk basic protein could recover alveolar bone loss in rat experimental periodontitis.

MATERIAL AND METHODS: A nylon ligature was placed around the cervix of molars in 8-wk-old male Fischer rats for 20 d. Then, the ligature was removed and a powder diet containing 0.2 or 1.0% milk basic protein was provided daily for another 45-90 d. On days 45 and 90, the maxillae were extracted and analyzed using microcomputerized tomography (micro-CT), followed by histological analysis.

RESULTS: Micro-CT images showed that alveolar bone resorption was severely induced around the molar by the 20-d ligature procedure. Treatment with high-dose milk basic protein (1.0%) clearly recovered ligature-induced alveolar bone resorption on days 45 and 90, whereas low-dose milk basic protein (0.2%) did not show such a clear effect. Histological examination clarified that the osteoid thickness of alveolar bone was dose dependently increased by milk basic protein treatment for 90 d.

CONCLUSION: These findings suggest that a systemic administration of milk basic protein may be effective for the recovery of alveolar bone loss in periodontitis.


The usefulness of strontium as an adjuvant to calcium in the remineralization of the skeleton in man.

Bull Hosp Joint Dis. 1952 Apr; 13(1): 59-66.

Shorr E, Carter AC.

The results are described of a current investigation of the possible value of Sr as an adjuvant to Ca in the remineralization of the depleted skeleton in a variety of derangements of bone metabolism in man. Sr, in amounts sufficient to achieve significant retention of this element, has been well tolerated over several years of administration and without toxic effects. The retention of Sr is augmented by agents such as Vitamin D, estrogens, and androgens in a similar manner to Ca. When given in equal amounts, Sr is found to have certain distinct advantages over Ca for the remineralization of the skeleton. There is greater retention of Sr; and when the ceiling for Ca retention has been reached, the addition of Sr results in a retention of the latter. Hence, the deposition of Ca plus Sr is greater than the total Ca storage which can be achieved with Ca alone, regardless of Ca intake and auxiliary therapy. This combination should hasten the rate of remineralization of the skeleton as compared with Ca alone, an inference that is supported by the objective and subjective improvement observed under the combined regime. Maximal retention of Sr and Ca is achieved with the assistance of three auxiliary agents-Vitamin D, estrogens and androgens. Finally, the usefulness of Sr as a means of measuring mineral salt turnover in bone is suggested.


The effect of strontium lactate in the treatment of osteoporosis.

Proc Staff Meetings Mayo Clin. 1959; 34(13): 329-34.

McCaslin FE Jr, Janes JM.

A study has been made of the case records of 32 patients treated for osteoporosis with strontium lactate, or strontium lactate with hormones, and then traced for various periods with repeated physical and roentgenographic examinations. Marked subjective improvement was experienced by 84 percent of the patients. Although the mechanism of action of strontium lactate in the treatment of osteoporosis remains to be elucidated, the therapeutic value of the drug appears to be established.


Histomorphometry of Bone Changes in Stable Strontium Therapy.

Trace Subst Env Health. 1985; 19: 193-208.

Marie PJ, Skoryna SC, Pivon RJ Chabot G, Glorieux FH, Stara JF

Previous studies in rats have shown that low dosage of stable Sr2 added to drinking water stimulates bone formation (7). Low doses of Sr2 are currently used in treating metastic bone cancer and osteoporosis (17). In the present paper, histomorphometric changes in transiliac bone biopsy material obtained in six patients, before and after 6 months of Stable Strontium Therapy (SST), are reported. All cases had clinically diagnosable osteoporosis. Sr2 was administered as Sr carbonate, 600-700mg per day. No side effects were observed. Serum Sr:Ca ratio changed from pre SST of 1:1250 (±176) to 1:12 (±0.35) post SST. Bone Sr:Ca ratio changed from 1:1276 (±852) to 1:166 (±74). Mean bone Ca2 increased slightly but not significantly. Following SST, all histological parameters of bone formation increased, while bone resorption remained unchanged. An increased amount of osteoid tissue was observed, associated with stimulation of bone formation at the tissue level. No significant elevation of trabecular bone volume was found. Clinical observations suggest that the response to SST is better in younger (post-menopausal) cases than in senile osteoporosis. Long-term studies are necessary to determine whether the increase in trabecular calcified bone volume observed in rodents, following low dosage of Sr2 , also occurs in human subjects.


Strontium ranelate reduces the risk of hip fractures in women with postmenopausal osteoporosis.

Osteoporos Int. 2002 Nov;13 (Suppl 3): S14(AbsO14).

Reginster J-Y, Sawicki A, Devogelaer JP, Padrin JM, Kaufma JM, Doyle DV, Fardellone P, Graham J, Felsenberg D, Tulassay Z, Soren-Sen OH, Luisett G, Rizzoli R, Blotman F, Pheneko C, Meunier PJ.

Preclinical and clinical studies have demonstrated that strontium ranelate (S12911) is a bone forming agent with anti-resorptive activity which increases bone mass and bone biomechanical resistance. A dose-ranging clinical study (STRATOS) has determined the 2g-daily dose to be the optimal dose in increasing lumbar BMD.

A randomised double-blind, placebo controlled, phase 3 clinical trial (SOTI study), involving 72 centres in 12 countries, was designed to assess the anti-vertebral fracture efficacy and safety of S12911 (2g/d orally) in women with postmenopausal osteoporosis over a 3 year period. Patients also received daily calcium and vitamin D supplements. The patients (n = 1649) were included in two parallel groups [age: 69.7 (7.3); Lumbar BMD: 0.73 (0.12); mean (SD)], 87.5% of them having at least one prevalent vertebral fracture (2.2 prevalent VF per patient). A 41% reduction in relative risk (RR) of experiencing a first new vertebral fracture (semi-quantitative assessment) was observed with strontium ranelate throughout the 3 year study compared to placebo, 139 patients with VF versus 222 respectively (RR = 0.59, 95%CI [0.48;0.73], p We infer that strontium ranelate is a new orally effective and safe treatment of vertebral osteoporosis with a unique mechanism of action. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.


The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.

N Engl J Med. 2004 Jan 29;350(5):459-68.

Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY.

BACKGROUND: Osteoporotic structural damage and bone fragility result from reduced bone formation and increased bone resorption. In a phase 2 clinical trial, strontium ranelate, an orally active drug that dissociates bone remodeling by increasing bone formation and decreasing bone resorption, has been shown to reduce the risk of vertebral fractures and to increase bone mineral density.

METHODS: To evaluate the efficacy of strontium ranelate in preventing vertebral fractures in a phase 3 trial, we randomly assigned 1649 postmenopausal women with osteoporosis (low bone mineral density) and at least one vertebral fracture to receive 2 g of oral strontium ranelate per day or placebo for three years. We gave calcium and vitamin D supplements to both groups before and during the study. Vertebral radiographs were obtained annually, and measurements of bone mineral density were performed every six months.

RESULTS: New vertebral fractures occurred in fewer patients in the strontium ranelate group than in the placebo group, with a risk reduction of 49 percent in the first year of treatment and 41 percent during the three-year study period (relative risk, 0.59; 95 percent confidence interval, 0.48 to 0.73). Strontium ranelate increased bone mineral density at month 36 by 14.4 percent at the lumbar spine and 8.3 percent at the femoral neck (P CONCLUSIONS: Treatment of postmenopausal osteoporosis with strontium ranelate leads to early and sustained reductions in the risk of vertebral fractures.


Mechanisms of action and therapeutic potential of strontium in bone.

Calcif Tissue Int 2001 Sep; 69(3): 121-9.

Marie PJ, Ammann P, Boivin G, Rey C.

The processes of bone resorption and formation are tightly governed by a variety of systemic and local regulatory agents. In addition, minerals and trace elements affect bone formation and resorption through direct or indirect effects on bone cells or bone mineral. Some trace elements closely chemically related to calcium, such as strontium (Sr), have pharmacological effects on bone when present at levels higher than those required for normal cell physiology. Indeed, strontium was found to exert several effects on bone cells. In addition to its antiresorptive activity, strontium was found to have anabolic activity in bone, and this may have significant beneficial effects on bone balance in normal and osteopenic animals. Accordingly, strontium has been thought to have potential interest in the treatment of osteoporosis. This review summarizes the mechanisms of action of strontium on bone cells, the evidence for its beneficial effects on bone mass in vivo, and its potential therapeutic effects in osteopenic disorders.


Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial.

Osteoporos Int 2002 Dec; 13(12): 925-31.

Reginster JY, Deroisy R, Dougados M, Jupsin I, Colette J, Roux C.

Early postmenopausal women ( n = 160) were randomised to receive placebo or strontium ranelate (SR) 125 mg/day, 500 mg/day or 1 g/day for 2 years (40 participants per group). All participants received calcium 500 mg/day. The primary efficacy parameter was the percent variation in lumbar bone mineral density (BMD), measured using dual-energy X-ray absorptiometry. Secondary efficacy criteria included hip BMD and biochemical markers of bone turnover. At month 24, SR 1 g/day significantly increased lumbar BMD compared with placebo [mean (SD) 5.53% (5.12);


image description
image description